ClinicalTrials.gg
RecruitingNCT04585204Updated Aug 15, 2024

Comparison of the Detection Rates of 50 Gr-100 Gr OGTT and 75 Gr OGTT That Require Medical Treatment of GDM

An interventional study of Oral glucose tolerance test in Gestational Diabetes and Glucose Intolerance During Pregnancy, sponsored by Ankara City Hospital Bilkent. Recruiting at 1 site in Turkey. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-15.

Sponsored by Ankara City Hospital Bilkent · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Oct 2020; still recruiting 6 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,282
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Diabetes, Gestational with a site in Turkey — 9 open to participants now, 12 under way, none of them phase 3. Diabetes, Gestational · Turkey.

Planned enrollment
Largest of 28
2,282 · median 85
Started
2020
with 3 others
No phase
28 of 52
5 open now
Primary completion
2024-12
later than 3 of 11 live
Registered
8th of 52
by date
Lead sponsor
3 of 52
Ankara City Hospital Bilkent

Among the 52 studies in Diabetes, Gestational with a site in Turkey, this one has the largest planned enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2020, is one of 28 with no phase, reaches primary completion later than 3 of the 11 other live ones, and was the 8th registered.

Diabetes, Gestational

878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.

Browse Diabetes, Gestational studies →

Open to participants now

9 of the 52 studies in Diabetes, Gestational with a site in Turkey are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Diabetes, Gestational with a site in Turkey, or all of them as a file.
02

Study summary

Both 50 gr OGTT-100 gr OGTT and 75 gr OGTT are used for detecting gestational diabetes mellitus. Two approaches are approved by obstetricians. With this study, we aim to compare the gestational diabetes mellitus detection rate of these different tests.

03

Conditions studied

  • Gestational Diabetes
  • Glucose Intolerance During Pregnancy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women

Exclusion criteria

Exclusion Criteria:

  • Already diagnosed by diabetes mellitus
  • Multiple pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,282 participants (estimated)

Study arms

  • Active comparator
    50 gr-100 gr OGTT

    patients are tested firstly by 50 gr OGTT after that if necessary by 100 gr OGTT

    Diagnostic Test: Oral glucose tolerance test

  • Active comparator
    75 gr OGTT

    patients are tested by 75 gr OGTT

    Diagnostic Test: Oral glucose tolerance test

Interventions

  • Diagnostic testOral glucose tolerance test

    Oral glucose tolerance test

06

What researchers measure

Primary outcomes

  1. the difference of GDM detection rate of 50 gr- 100 gr OGTT and 75 gr OGTT

    to determine the ideal diagnostic test

    Time frame: one year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2020 (actual). Primary completion is estimated for Dec 2024, 50 months after the start.

Of 306 non-industry interventional studies with no phase under Diabetes, Gestational, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's planned 50 months is above that.

Counting every sponsor, half of 309 studies reached it within 28 months; a quarter within 13 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2020
First posted
Oct 14, 2020
StartActual
Oct 1, 2020
Primary completionEst.
Dec 1, 2024
CompletionEst.
Dec 1, 2024
Last update
Aug 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04585204
Responsible party
Sponsor
First posted
Oct 14, 2020
Start date
Oct 1, 2020
Primary completion
Dec 1, 2024 (estimated)
Completion
Dec 1, 2024 (estimated)
Last update
Aug 15, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion